Navigation Links
Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4
Date:7/31/2013

t as may be required by law.

Statement Required by the Irish Takeover RulesThe directors of Actavis accept responsibility for the information contained in this announcement other than that relating to Warner Chilcott and its Associates and the directors of Warner Chilcott and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the directors of Actavis (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

The directors of Warner Chilcott accept responsibility for the information contained in this announcement relating to Warner Chilcott and its Associates and the directors of Warner Chilcott and members of their immediate families, related trusts and persons connected with them. To the best of the knowledge and belief of the directors of Warner Chilcott (who have taken all reasonable care to ensure such is the case), the information contained in this announcement for which they accept responsibility is in accordance with the facts and does not omit anything likely to affect the import of such information.

BofA Merrill Lynch and Greenhill & Co. are acting exclusively for Actavis and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than Actavis for providing the protections afforded to clients of BofA Merrill Lynch or Greenhill & Co and for providing advice in relation to the acquisition of Warner Chilcott, the contents of this announcement or any transaction or arrangement referred to herein.

Deutsche Bank Securities Inc. is acting for Warner Chilcott as financial advisor and is not acting as financial advisor to anyone else in connection with the matters referred to in this announcem
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
10. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
11. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of its previously announced underwritten public offering of ... public offering price of $11.25 per share. The ... 1,000,000 shares issued upon the exercise in full ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015  Eisai ... Ltd. (Headquarters: Tokyo , President and ... Inc. (Headquarters: San Diego, California , ... HALO") have signed a clinical collaboration agreement to evaluate ... in combination with Halozyme,s investigational drug PEGPH20 (PEGylated recombinant ...
(Date:7/31/2015)... CHICAGO , July 31, 2015 ... Composition Analyzers Market by Product (Bioimpedance Analyzers (BIA), Dual-Energy ... and Hydrostatic Weighing) - Global Analysis & Forecast to ... Market was pegged at $911.1 Million 2014 and is ... at a CAGR of 9.4% from 2014 to 2019. ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
(Date:7/31/2015)... ... 2015 , ... Transfinder, a software company based in Schenectady, N.Y., achieved record ... year-over-year for the first six months ended June 30, 2015 compared with the same ... last year’s record-revenue mark of $10.4 million. , “We know what our customers need ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System will work ... the potential of related, experimental treatments. The collaboration moves into the next phase with ... Care one of five state licenses to produce and dispense medical marijuana. , ...
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export ... http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ports costs time, money ... risking containment — or even destruction — of products, an FDA insider shows ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... Patients ... disease, according to a study published today in Nature Communications and led by researchers ... in mice, suggests that variations in the gene RTN1 led to greater production of ...
(Date:7/31/2015)... ... ... Down is a reputable source of authentic USA vs. Australia tickets at Ford ... National Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World ... team was awarded the Golden Ball as the best player of the 2015 Women's World ...
Breaking Medicine News(10 mins):Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... the most commonly reported vector-borne disease in the United States, ... has been three decades since the agent of the disease, ... vector it were identified. However, the number of Lyme disease ... in the forthcoming issuue of the Journal of Medical ...
... Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- Some people ... chemotherapy, and a mutation in the so-called TFAP2E gene may ... Knowing which patients carry the mutation might help ... researchers said. "In our study, we identified a gene ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Jan. ... and deaths in the United States in recent years are charted ... for cancer went down by 1.8 percent a year in men ... (ACS) reported Wednesday. And from 1990 through 2008, death rates ...
... 2012-PORTLAND, Ore. When patients with diabetes experience interruptions in ... the screening tests and vaccines they need to protect their ... when patients receive free or reduced-cost medical care at federally ... part by the National Institutes of Health and findings published ...
... , WEDNESDAY, Jan. 4 (HealthDay News) -- Remember those ... but you took the plunge and whizzed downward. Next, ... and hanging by your knees at the pinnacle. ... sliding boards, safer plastic climbers and fence-protected platforms are ...
... ANGELES Marianne Gausche-Hill, M.D., and Kate Remick, M.D. ... Institute at Harbor-UCLA Medical Center (LA BioMed) are ... Jan. 6, 2012 that will help assess the pediatric ... the first statewide survey of its kind, this project ...
Cached Medicine News:Health News:How can Lyme disease be prevented and controlled? 2Health News:Gene Mutation Linked to Chemo-Resistant Colon Cancer 2Health News:Cancer Incidence, Death Rates Continue to Drop: Report 2Health News:Cancer Incidence, Death Rates Continue to Drop: Report 3Health News:Kaiser Permanente study finds continuous health coverage essential for patients managing diabetes 2Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 2Health News:'Safety-First' Playgrounds Linked to Bored, Inactive Kids: Study 3Health News:LA BioMed investigators lead first survey to determine hospital EDs' pediatric readiness 2
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Silicone ICD lead...
Medicine Products: